SCHEMBL77738

SCHEMBL77738

CC1(c2ccccc2)C(=O)NC(=O)NC1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 1.00
MMP9 P14780 6/20 1.00
MMP13 P45452 4/20 0.70
MMP3 P08254 3/20 0.70
MMP8 P22894 2/20 0.70
CACNA1F O60840 1/20 0.52
ALDH1A1 P00352 1/20 0.52
MAPT P10636 1/20 0.52
CYP2C9 P11712 1/20 0.52
HTR2A P28223 1/20 0.52
HRH1 P35367 1/20 0.52
SCN1A P35498 1/20 0.52
SCN4A P35499 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
CACNA1D Q01668 1/20 0.52
KCNH2 Q12809 1/20 0.52
CACNA1S Q13698 1/20 0.52
CACNA1C Q13936 1/20 0.52
SCN5A Q14524 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4321603 0.83 MMP2 (1.00) MMP2MMP9MMP13MMP3MMP8
SCHEMBL18622047 0.78 MMP2 (0.64) MMP2MMP9MMP13MMP3MMP8
SCHEMBL713351 0.76 MMP9 (0.61) MMP2MMP9MMP13MMP3MMP8
SCHEMBL18197230 0.75 LMNA (0.61) MMP2MMP9MMP13MMP3MMP8
SCHEMBL4548022 0.75 LMNA (0.61) MMP2MMP9MMP13MMP3MMP8
SCHEMBL3195931 0.74 MMP9 (0.59) MMP2MMP9MMP13MMP3MMP8
SCHEMBL1861823 0.74 MMP9 (0.59) MMP2MMP9MMP13MMP3MMP8
SCHEMBL3207324 0.74 MMP9 (0.59) MMP2MMP9MMP13MMP3MMP8
SCHEMBL4384462 0.74 ALDH1A1 (0.59) MMP2MMP9CACNA1FALDH1A1MAPT
SCHEMBL542865 0.74 ALDH1A1 (0.59) MMP2MMP9CACNA1FALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 951 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636254-B2 Stabilization of phenobarbital sodium for injection SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2026-05-26 US claimed
US-20240316049-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2024-09-26 US claimed
US-20240082161-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2024-03-14 US claimed
US-11857683-B2 Stabilization of phenobarbital sodium for injection SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2024-01-02 US claimed
WO-2023175542-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2023-09-21 WO claimed
US-20230031957-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2023-02-02 US claimed
WO-2023281441-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) 2023-01-12 WO claimed
CN-115583918-A Preparation method of methyl phenobarbital 精华制药集团南通有限公司 2023-01-10 CN claimed
WO-2021054927-A2 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2021-03-25 WO claimed
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS SOUTH DAKOTA BOARD OF REGENTS (US) 2020-02-13 US claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 EP claimed
WO-2011132171-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 WO claimed
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-10-27 US claimed
EP-2026788-A1 THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS SCHWARZ PHARMA AG (DE) 2009-02-25 EP claimed
WO-2007141018-A1 THERAPEUTIC COMBINATION FOR PAINFUL MEDICAL CONDITIONS SCHWARZ PHARMA AG (DE) 2007-12-13 WO claimed
US-20070043120-A1 Therapeutic combination for painful medical conditions UCB PHARMA GMBH (DE) 2007-02-22 US claimed
US-20070042969-A1 Combination therapy for pain in painful diabetic neuropathy SRZ PROPERTIES, INC. (US) 2007-02-22 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240082161-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION PYGB, EPM2A, CACNA1A MMP2 1007/4885MMP9 2479/4885MMP13 1858/4885
US-20070042969-A1 Combination therapy for pain in painful diabetic neuropathy GRIN2B, GRIN2A, GRIN3A MMP2 854/4885MMP9 1201/4885MMP13 401/4885
US-12636254-B2 Stabilization of phenobarbital sodium for injection SCN2B, CACNA1A, CYP3A5 MMP2 1978/4885MMP9 1474/4885MMP13 1322/4885
US-20230031957-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION EPM2A, PYGB, ATP6V1B2 MMP2 1175/4885MMP9 2497/4885MMP13 1819/4885
US-20200048305-A1 GLUTATHIONE-CHOLESTEROL DERIVATIVES AS BRAIN TARGETING AGENTS GSTK1, GSTO1, GSTM2 MMP2 1396/4885MMP9 1454/4885MMP13 2583/4885
US-20110263526-A1 Nitric Oxide Releasing Prodrugs of Therapeutic Agents NOS2, NOS1, NOS3 MMP2 1138/4885MMP9 1280/4885MMP13 2063/4885
US-11857683-B2 Stabilization of phenobarbital sodium for injection EPM2A, PYGB, ATP6V1B2 MMP2 1175/4885MMP9 2497/4885MMP13 1819/4885
US-20240316049-A1 STABILIZATION OF PHENOBARBITAL SODIUM FOR INJECTION EPM2A, PYGB, ATP6V1B2 MMP2 1169/4885MMP9 2633/4885MMP13 1901/4885
US-20070043120-A1 Therapeutic combination for painful medical conditions PDE1B, CA2, CACNA1S MMP2 467/4885MMP9 543/4885MMP13 169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.